Open AccessLong-Term Compassionate Use of Cefiderocol To Treat Chronic Osteomyelitis Caused by Extensively Drug-Resistant Pseudomonas aeruginosa and Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae in a Pediatric Patient
Author(s) -
Zain Alamarat,
Jessica T. Babic,
Truc T. Tran,
Susan H. Wootton,
An Q Dinh,
William R. Miller,
Blake Hanson,
Audrey Wanger,
Joshua L. Gary,
César A. Arias,
Norma Pérez
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01872-19
Subject(s) - aztreonam , pseudomonas aeruginosa , klebsiella pneumoniae , medicine , colistin , microbiology and biotechnology , ceftazidime , osteomyelitis , cephalosporin , antibiotics , biology , surgery , bacteria , biochemistry , genetics , escherichia coli , gene
We report a 15 year-old Nigerian adolescent male with chronic osteomyelitis caused by an extensively drug-resistant (XDR) Pseudomonas aeruginosa strain of sequence type 773 (ST773) carrying bla NDM-1 and an extended spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae strain. The patient developed neurological side effects in the form of circumoral paresthesia with polymyxin B and asymptomatic elevation of transaminases with aztreonam (used in combination with ceftazidime-avibactam). Cefiderocol treatment for 14 weeks plus bone implantation resulted in apparent cure and avoided amputation.